Sushanta Sarkar

Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization,<i>in vitro</i>and<i>in vivo</i>anti-prostate cancer activity, and mechanisms of action

Sukesh Voruganti, Jiang‐Jiang Qin, Sushanta Sarkar et al. · Oncotarget · 2015 · 63 citations · Full text

Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis

Jiang‐Jiang Qin, Wei Wang, Sushanta Sarkar et al. · Journal of Controlled Release · 2016 · 41 citations · Full text

Nanoparticles, Nanomedicine, Engineering +9

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy

Jiang‐Jiang Qin, Wei Wang, Sushanta Sarkar et al. · Oncotarget · 2016 · 28 citations · Full text

Breast Oncology, Nfat1-mdm2 Pathway, Medicine +14

RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy

Sukesh Voruganti, Fangxiu Xu, Jiang‐Jiang Qin et al. · Cancer Letters · 2015 · 27 citations · Full text

Tumor Cell Growth, Medicine, Pathology +9

Formulation and evaluation of matrix microspheres for simultaneous delivery of salbutamol sulphate and theophylline

Lalduhsanga Pachuau, Sushanta Sarkar, Bhaskar Mazumder · Tropical Journal of Pharmaceutical Research · 2008 · 23 citations · Full text

Pharmaceutical Science, Engineering, Biomedical Engineering +16